Dermagraft's Unit Acquisition

Dermagraft raised a round of funding on January 17, 2014. Investors include Organogenesis.

Dermagraft is a cryopreserved human-fibroblast –derived dermal substitute; it is composed of fibroblasts, extracellular matrix, and a bioabsorbable scaffold. Dermagraft is indicated for use in the t…

Articles about Dermagraft's Unit Acquisition: